Front Cover: Cholinesterase Inhibitory Activity and Molecular Docking Studies of Isocryptolepine-Triazole Adducts (ChemMedChem 24/2024)

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL ChemMedChem Pub Date : 2024-12-16 DOI:10.1002/cmdc.202482401

Jumreang Tummatorn, Ittipat Meewan, Nisachon Khunnawutmanotham, Nitirat Chimnoi, Nutchapong Suwanwong, Warabhorn Rodphon, Charnsak Thongsornkleeb, Jingyue Yang, Somsak Ruchirawat

{"title":"Front Cover: Cholinesterase Inhibitory Activity and Molecular Docking Studies of Isocryptolepine-Triazole Adducts (ChemMedChem 24/2024)","authors":"Jumreang Tummatorn, Ittipat Meewan, Nisachon Khunnawutmanotham, Nitirat Chimnoi, Nutchapong Suwanwong, Warabhorn Rodphon, Charnsak Thongsornkleeb, Jingyue Yang, Somsak Ruchirawat","doi":"10.1002/cmdc.202482401","DOIUrl":null,"url":null,"abstract":"<p>This illustration depicts the molecular interactions of isocryptolepine-triazole hybrids with Acetylcholinesterase (AChE) in the brain related to Alzheimer′s disease. Central to the image is AChE, an enzyme involved in neurotransmitter regulation. Surrounding AChE are potential new compounds designed to inhibit its activity, thereby enhancing cholinergic signaling and potentially alleviating symptoms of Alzheimer′s. The visual emphasizes the innovative research aimed at developing effective therapeutics for this progressive neurodegenerative disorder. More details can be found in article 10.1002/cmdc.202400447 by Jumreang Tummatorn, Nutchapong Suwanwong, and co-workers.<figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"19 24","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202482401","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202482401","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

This illustration depicts the molecular interactions of isocryptolepine-triazole hybrids with Acetylcholinesterase (AChE) in the brain related to Alzheimer′s disease. Central to the image is AChE, an enzyme involved in neurotransmitter regulation. Surrounding AChE are potential new compounds designed to inhibit its activity, thereby enhancing cholinergic signaling and potentially alleviating symptoms of Alzheimer′s. The visual emphasizes the innovative research aimed at developing effective therapeutics for this progressive neurodegenerative disorder. More details can be found in article 10.1002/cmdc.202400447 by Jumreang Tummatorn, Nutchapong Suwanwong, and co-workers.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

封面：异cryptolepine- triazole加合物胆碱酯酶抑制活性及分子对接研究（ChemMedChem 24/2024）

这幅插图描绘了异克雷托平-三唑杂合体与大脑中与阿尔茨海默病相关的乙酰胆碱酯酶（AChE）的分子相互作用。图像的中心是乙酰胆碱酯酶，一种参与神经递质调节的酶。AChE周围是潜在的新化合物，旨在抑制其活性，从而增强胆碱能信号传导，并可能减轻阿尔茨海默病的症状。视觉强调旨在开发有效治疗这种进行性神经退行性疾病的创新研究。更多细节可以在10.1002/cmdc中找到。Jumreang Tummatorn， Nutchapong Suwanwong及其同事2012400447

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.